11 hours Ago By Timothy Alexander
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) unveiled encouraging clinical data for its investigational therapy, VP-315, at the 2025 Winter Clinical Dermatology Conference in Miami, Florida. The Phase 2 study findings highlighted a notable 97% calculated objective response rate (ORR) for the treatment of basal cell carcinoma (BCC), offering potential for a groundbreaking non-surgical alternative to current invasive treatments.
The data, derived from Part 2 of the study, showed that 51% of tumors achieved complete histological clearance, with remaining tumors experiencing a significant size reduction averaging 71%. Most treatment-related adverse events were mild to moderate, and no serious adverse events were reported in the trial, which enrolled 82 patients across 91 target tumors. “We remain highly encouraged by the positive preliminary topline results from Part 2 of the Phase 2 study for VP-315,” said Dr.
Jayson Rieger, President and CEO of Verrica. He further emphasized the potential for VP-315 to shift the treatment paradigm in BCC, noting its promise as a first-line, non-invasive therapy for millions of patients diagnosed annually in the U.S.
VP-315, administered intratumorally, is an oncolytic chemotherapeutic peptide immunotherapy designed to induce immunogenic cell death and trigger a T-cell response. Verrica plans an End-of-Phase 2 meeting with the FDA in the first half of 2025 to determine the next steps for advancing this innovative therapy toward regulatory approval. With basal cell carcinoma remaining the most common cancer in the United States, Verrica’s VP-315 could represent a significant leap forward, addressing the unmet need for less invasive treatments and offering relief to patients facing painful surgical procedures.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN ..
